Protocol summary
-
Study aim
-
Eevaluation the efficacy of oral supplement omega-3 in treatment of recurrent aphthous stomatitis
and improvement of oral health related quality of life
-
Design
-
In this double-blind clinical trial, 40 patients with recurrent aphthous stomatitis who referred to the Oral Medicine Department of the Faculty of Dentistry of Babol University of Medical Sciences were selected. After matching with the inclusion and exclusion criteria, these individuals are randomly ( flip the coin) assigned to two groups of 20 control and intervention groups. The placebo group receives placebo capsules and the intervention group receives omega-3 capsules (DeraPakhsh, Iran).
-
Settings and conduct
-
The participants were selected from patients referred to the clinic of oral medicine department of the faculty of dentistry of Babol university of medical sciences. Participants who met the inclusion/exclusion criteria received verbal information about the study. Intervention group received omega-3 capsules of 1000 mg each (Zahravi Company, Tehran, Iran) tree times a day for six month and control group received placebo capsules with the same prescription.
At baseline appointment and monthly follow-up visits (for 6 months), a questionnaire for the average number of ulcers, the amount of pain (VAS), and the amount of time of the wound present are filled for each patient. patients filled persian version of the chronic oral mucosal disease questionnaie (COMDQ) were ranked by the patients To evaluate treatment effectiveness two times: at the baseline appointment and 6 months later.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria in case and control groups:
both male and female with older than18 years of age; having recurrent minor aphthous ulcer for at least 1 year ; presenting with 1 to 3 aphthous ulcers (of less than 48 hours’ duration)
exclusion criteria in case and control groups: individuals heart, liver, or kidneys disease; pregnancy or lactation; ulcers as a manifestation of systemic disorders such as ulcerative colitis, Crohn disease, Behçet syndrome ; use of medications such as systemic steroids,immunomodulatory agents, or nonsteroidal anti-inflammatory drugs within 1 month before study entry.
-
Intervention groups
-
experimental group (omega-3 group) included patients with recurrent aphtous stomatitis who received omega-3 soft gelatin capsules(Zahravi Company, Tehran, Iran) of 1000 mg 3 times daily
control group (placebo group) included patients with recurrent aphthous stomatitis who received placebo soft gelatin capsules 3 times daily
-
Main outcome variables
-
number of new ulcer outbreaksک the average level of pain using a visual analog scale (VAS); the average duration of ulcer episodes; the average score of COMDQ
General information
-
Reason for update
-
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20160112025986N3
Registration date:
2018-01-07, 1396/10/17
Registration timing:
registered_while_recruiting
Last update:
2018-01-07, 1396/10/17
Update count:
1
-
Registration date
-
2018-01-07, 1396/10/17
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2017-12-22, 1396/10/01
-
Expected recruitment end date
-
2018-06-22, 1397/04/01
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Efficacy of oral supplement omega-3 in treatment of recurrent aphthous stomatitis and improvement of oral health related quality of life
-
Public title
-
Efficacy of oral supplement omega-3 in treatment of recurrent aphthous stomatitis
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
both male and female with older than18 years of age
having recurrent minor aphthous ulcer for at least 1 year with a frequency of at least 1 outbreak per month
presenting with 1 to 3 aphthous ulcers (of less than 48 hours’ duration) with a size no greater than10 mm in diameter
withoutanesthesia or paresthesia
Exclusion criteria:
individuals who had concurrent clinical conditions that could pose a health risk to the participants,including serious heart, liver, or kidneydys functions
pregnancy or lactation
ulcers as a manifestationof systemic disorders such as ulcerative colitis, Crohn disease, Behçet syndrome, or serious anemia
use of medications such as systemic steroids,immunomodulatory agents, antibiotics, or nonsteroidalanti-inflammatory drugs within 1 month before study entry
-
Age
-
From 18 years old
-
Gender
-
Both
-
Phase
-
N/A
-
Groups that have been masked
-
- Participant
- Care provider
- Investigator
- Outcome assessor
-
Sample size
-
Target sample size:
40
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
In this study, individuals were randomly divided into two groups of omega-3 capsules and placebo capsules using coin throwing.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
In order to eliminate the error from the knowledge of the patient or assessor's dentist to the type of treatment received and its possible impact on the outcome of the study, a double-blind study is done. Given that the omega-3 capsules and placebo are placed in the same full capsule, the patient and the assessing dentist are not aware of the type of medication received.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2017-10-15, 1396/07/23
-
Ethics committee reference number
-
MUBABOL.REC.1396.67
Health conditions studied
1
-
Description of health condition studied
-
Recurrent Aphtous Stomatitis
-
ICD-10 code
-
K12.0
-
ICD-10 code description
-
Recurrent oral aphthae
Primary outcomes
1
-
Description
-
Number of aphtous ulcer
-
Timepoint
-
First appointment; monthly for 6 months
-
Method of measurement
-
Count the ulcers
2
-
Description
-
Level of pain
-
Timepoint
-
First appointment, monthly for 6 months
-
Method of measurement
-
Visual Analogue Scale (VAS )
3
-
Description
-
average duration of ulcer episodes
-
Timepoint
-
First appointment; monthly for 6 months
-
Method of measurement
-
Number of days
4
-
Description
-
The average score of COMDQ
-
Timepoint
-
First appointment; 6 month later
-
Method of measurement
-
Filling the questionnaire
Intervention groups
1
-
Description
-
Intervention group: omega-3 soft gelatin capsules(Zahravi Company, Tehran, Iran) of 1000 mg 3 times daily , 6 months
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: placebo soft gelatin capsules 3 times daily for 6 months
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Babol University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
No - There is not a plan to make this available
-
Statistical Analysis Plan
-
Not applicable
-
Informed Consent Form
-
No - There is not a plan to make this available
-
Clinical Study Report
-
Not applicable
-
Analytic Code
-
Not applicable
-
Data Dictionary
-
Not applicable